📰 Dose Management News

Page 4 - Dose Management News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Dose Management. Real-time updates on events, politics, business and more.

Biogen Inc.: FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

June 9, 2023

Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's disease The

South Korea United States United Kingdom New Zealand Great Britain Christophera Viehbacher

Source: finanznachrichten.de

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

June 9, 2023

Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.

New Zealand South Korea United States United Kingdom Great Britain Haruo Naito

Source: theglobeandmail.com

Stock Market | FinancialContent Business Page

June 9, 2023

FinancialContent fully hosted finance channel

United Kingdom South Korea United States New Zealand Great Britain Jack Cox

Source: financialcontent.com

U.S. Veterans' Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early

March 14, 2023

STOCKHOLM, March 14, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...

Uppsala Lan Oskar Bosson Uppsala University Vp Communications National Institutes Of Health National Institute On

Source: europapress.es

BioArctic: U.S. Veterans' Health Administration (VHA) provides coverage of LEQEMBI (lecanemab-irmb) for veterans living with early stages of Alzheimer's disease

March 14, 2023

STOCKHOLM, March 14, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing coverage

Uppsala Lan Oskar Bosson Dennis Riedl Uppsala University Vp Communications National Institutes Of Health

Source: finanznachrichten.de

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

U.S. Veterans' Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer's disease

March 14, 2023

/PRNewswire/ -- BioArctic ABs (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing...

Uppsala Lan Oskar Bosson Uppsala University Vp Communications National Institutes Of Health National Institute On

Source: prnewswire.com

U.S. VETERANS' HEALTH ADMINISTRATION (VHA) PROVIDES COVERAGE OF LEQEMBI™ (LECANEMAB-IRMB) TWO MONTHS AFTER LEQEMBI'S FDA ACCELERATED APPROVAL FOR VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER'S DISEASE

March 13, 2023

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the U.S. Veterans Health Administration (VHA) is...

New Zealand United Kingdom Haruo Naito Libby Holman Prnewswire Eisai Co Ltd Communications Department

Source: prnewswire.com

Biogen Inc.: FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

March 6, 2023

Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with

New Zealand United Kingdom United States Dennis Riedl Haruo Naito Christophera Viehbacher

Source: finanznachrichten.de